Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Myriad Genetics (MYGN) and PATHOMIQ entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology platform for prostate cancer, in the United States.

LIMA, Peru, Dec. 1, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, announced a partnership with the ...

Founded in 2021, T3 Molecular Genetics Pvt Ltd. (T-3MGen) operates in the Health Tech sector offering new therapeutic interventions through multi-disciplinary ...

The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook.

What we choose to study—whether fine art or finance—is one of the most influential decisions in our lives. It shapes not only ...